Mifamurtide
DCTPepD ID DCTPepD0011
Active Ingredients Mifamurtide
Description A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.
Synonyms CGP 19835A Lipid; Junovan; L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-((7R)-4-hydroxy-4-oxido-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, Monosodium Salt, Hydrate; L-MTP-PE; Mepact; MTP-PE Liposome; muramyl tripeptide phosphatidylethanolamine; Muramyl Tripeptide Phosphatidylethanolamine Liposome; MuramylNAc-Ala-isoGln-Lys-tripeptide-PE; Mifamurtide
Disease Osteosarcoma
Classification
Immunomodulator Peptide and derivative MDP derivative
Structure Information
Molecular Formula C59H108N6O19P.Na.H2O
Molecular Weight 1277.5
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name sodium;2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl 2,3-di(hexadecanoyloxy)propyl phosphate;hydrate
InChI InChI=1S/C59H109N6O19P.Na.H2O/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68;;/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79);;1H2/q;+1;/p-1
InChI_Key NGIYLSFJGRLEMI-UHFFFAOYSA-M
SMILES CCCCCCCCCCCCCCCC(OCC(OC(CCCCCCCCCCCCCCC)=O)COP([O-])(OCCNC(C(NC(CCC(NC(C(NC(C(OC(C(O)C(O)CO)C(NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)=O)=O.[H]O[H].[Na+]
External Codes
PubChem CID 123133557
DrugBank Accession Number DB13615
NCI Thesaurus Code C1394
UNII 1LM890Q4FY GSRS
CAS 838853-48-8
Drug approval
Drug indication
Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy.
| Drug Name | Strength | Dosage Form/Route | Company | Marketing Status | Drug ID | Approval year |
|---|---|---|---|---|---|---|
| Mepact | 4 mg | Powder; Intravenous | Takeda France Sas | Prescription | EMEA/H/C/000802 | 2009 |
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT03643133 | Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) | Osteosarcoma | Phase 2 | Treatment |
| NCT00631631 | Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) for High-risk Osteosarcoma | Osteosarcoma | Treatment | |
| NCT02441309 | A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma | Osteosarcoma | Phase 2 | Treatment |
| NCT01459484 | ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2) | Osteosarcoma | Phase 2 | Treatment |
| NCT04062721 | Feasibility and Safety of Local Immunomodulation Combined With Radiofrequency Ablation for Unresectable Colorectal Liver Metastases: A Monocentric Phase I Trial | Unresectable Colorectal Liver Metastases | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
